MIT Biotechnology Group

Frank David (Pharmagellan) Biotech Forecasts and Valuation Models 10/18 4PM

Join us to hear from Frank DavidMD, PhD, co-author of “The Pharmagellan Guide to Biotech Forecasting and Valuation”, about valuing biotech assets (small molecule drugs, biologics), a crucial exercise when evaluating publicly traded biotech companies, licensing deals, potential M&A, early-stage venture investments, and even your own biotech startup!

  • “All models are wrong, but some are useful” – How to approach financial models in biotech

  • Patients, patients, patients – The importance of bottom-up market sizing

  • Resisting the siren call of customization – How and when to adjust literature values for key inputs

  • “We’re only worth WHAT?” – Managing expectations of the “consumers” of biotech models

Wednesday 10/18 @ 4:00 PM
NOTE: EVENT LOCATION HAS BEEN CHANGED TO: 415 Main Street (Broad Institute), 2nd floor, Monadnock room. 
Refreshments will be provided

2 Responses

Leave a Reply